Nuss G W, Smyth R D, Breder C H, Hitchings M J, Mir G N, Reavey-Cantwell N H
Agents Actions. 1976 Nov;6(6):735-47. doi: 10.1007/BF02026097.
Fenclorac (a,m-dichloro-p-cyclohexlphenylacetic acid, diethylammonium salt) is a potent nonsteroidal anti-inflammatory agent with significant analgesic and antipyretic activity. Fenclorac had an ED50 of 7.9 mg/kg in the carrageenan paw edema assay and had a duration of action of 18-22 hours. Comparative tests in the carrageenan paw edema assay in the rat indicated that the potency of fenclorac was 13 times that of aspirin, 3.4 times phenylbutazone, 3 times ibuprofen and 0.3 times indomethacin. Fenclorac was less potent than indomethacin, but more potent than phenylbutazone or aspirin in treatment of developing or established adjuvant arthritis. The anti-inflammatory effectiveness of fenclorac did not depend upon the integrity of the adrenopituitary axis and was not affected by the route of administration or sex of the test animal. Fenclorac was 77 times more potent than aspirin and more than twice as potent as indomethacin in reducing fever in rats rendered hyperthermic with brewer's yeast. Fenclorac did not affect normal body temperatures. Fenclorac did not interfere with cellular immune mechanisms as measured by its lack of effectiveness in experimental allergic encephalomyelitis. Antinociceptive testing indicated that fenclorac had peripheral but not central analgesic activity. Fenclorac had an acute oral LD50 in rats and mice of 285 and 430 mg/kg, respectively. The acute gastric lesion UD50 for fenclorac was 7 mg/kg in the fasted rat. Studies using 51Cr-tagged erythrocytes indicated that fenclorac did not produce significant fecal blood loss in the rat at twice the therapeutic ED50 dose for up to 12 days after dosing. Extensive and prolonged fecal blood loss was observed with a corresponding dose of indomethacin for up to nine days after administration. Comparison of the anti-inflammatory pharmacology, Therapeutic Ratio and the data obtained from the 51Cr-fecal blood loss studies indicated that fenclorac was well tolerated after acute or subacute administration to the rat.
芬氯那酸(α,间二氯对环己基苯乙酸二乙铵盐)是一种强效非甾体抗炎药,具有显著的镇痛和解热活性。在角叉菜胶致大鼠足爪肿胀试验中,芬氯那酸的半数有效量(ED50)为7.9毫克/千克,作用持续时间为18 - 22小时。在大鼠角叉菜胶致足爪肿胀试验中的对比试验表明,芬氯那酸的效力是阿司匹林的13倍、保泰松的3.4倍、布洛芬的3倍以及吲哚美辛的0.3倍。在治疗正在发展的或已形成的佐剂性关节炎方面,芬氯那酸的效力低于吲哚美辛,但高于保泰松或阿司匹林。芬氯那酸的抗炎效果不依赖于肾上腺垂体轴的完整性,且不受给药途径或试验动物性别的影响。在使大鼠因啤酒酵母而发热的模型中,芬氯那酸降低体温的效力比阿司匹林高77倍,比吲哚美辛高两倍多。芬氯那酸不影响正常体温。在实验性过敏性脑脊髓炎中,芬氯那酸因缺乏有效性而未干扰细胞免疫机制。抗伤害感受测试表明,芬氯那酸具有外周而非中枢镇痛活性。芬氯那酸对大鼠和小鼠的急性经口半数致死量(LD50)分别为285毫克/千克和430毫克/千克。在禁食大鼠中,芬氯那酸的急性胃损伤半数有效量(UD50)为7毫克/千克。使用51铬标记红细胞的研究表明,在给药后长达12天内,给予两倍治疗量ED50的芬氯那酸未使大鼠出现显著的粪便失血。给予相应剂量的吲哚美辛后,在给药后长达九天观察到广泛且持续的粪便失血。抗炎药理学、治疗指数以及51铬粪便失血研究所得数据的比较表明,大鼠急性或亚急性给予芬氯那酸后耐受性良好。